Corrective Phases R...
Agenus Inc. (AGEN: NASDAQ)
$2.48 0.06 | 2.48%
12/01/11 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 5.07 |
| 52 Week High | 7.41 |
| 52 Week Low | 1.92 |
| Avg. Daily Vol. (Mil) | 0.31 |
| Beta (3 year) | 1.61 |
| Share Related Items | |
| Mkt Cap (Mil) | 115.52 |
| Shares Out (Mil) | 22.79 |
| Float (Mil) | 20.97 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.50 |
| Current Ratio | 4.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 7.47 |
| Price/Book | 0.00 |
| Price/Cash Flow | -12.70 |
| Per Share Data | |
| Earnings | -0.58 |
| Sales | 0.68 |
| Book Value | 0.00 |
| Cash Flow | -0.40 |
| Business Summary | |
|---|---|
| Agenus, Inc. is a biotechnology company, which is developing and commercializing technologies to treat cancers and infectious diseases, based on immunological approaches. | |
| General Information | |
| 3 Forbes Road
Lexington, MA 02421 |
|
| www.antigenics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 54 | |
| CEO: Dr. Garo H Armen PhD | |
| Short Interest | |
| Current Month (Mil) | 0.55 |
| Previous Month (Mil) | 0.71 |
| Short Interest Ratio (Days) | 2.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -31.80 |
| Return on Investments | -62.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -39.70 |
| Profit Margin | -68.20 |
Portfolios with AGEN
- Portfolio NameUser Type
- UserKJP Save Stockpickr Fund
- ContributorStocks Under-$10 Moving Hig...
- ProRobert Bruce
- Contributor16 Small-Cap Stocks in Dang...
- UserASCO 2010
- Userhp22puch Portfolio 1
- Usernvoelz Portfolio 1
- UserPix's Stocks
- UserArsenD Portfolio 1
- UserMikejo10 Portfolio 1
Latest AGEN Headlines from TheStreet
- Biotech Stock Mailbag: All You Need to Know About Hep C Drugs 04.13.12 | 05:04 am
- 3 Stocks Under $10 Moving Higher 03.29.12 | 12:03 pm
- Agenus' CEO Discusses Q4 2011 Results - Earnings Call Transcript 03.05.12 | 03:03 pm
- Agenus Only Gets A Mosquito-Sized Bite of the New And Heralded Malaria Vaccine 10.18.11 | 03:10 pm
- Agenus Stock Gaps Down On Today's Open (AGEN) 10.07.11 | 09:10 am
- Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.29.11 | 10:07 pm
- Oncothyreon: Deep Dive Into Stimuvax 07.11.11 | 07:07 am
- Biotech Data Mining Comes Up Empty 06.29.11 | 07:06 am
- ASCO: Cancer Stock Winners, Losers 05.19.11 | 10:05 am
- Agenus Receives NASDAQ Delisting Notification 03.04.11 | 09:03 am
Press Releases for AGEN
- The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical Development - Business Wire 08.25.10 | 02:08 pm
- Antigenics Reports Second Quarter 2010 Financial Results - Business Wire 07.29.10 | 07:07 am
- Antigenics Presents Positive, Top Line Data From Phase I Herpes Clinical Trial - Business Wire 07.27.10 | 07:07 am
- Antigenics To Report Second Quarter Financial Results On July 29, 2010; Conference Call To Follow - Business Wire 07.22.10 | 07:07 am
- Antigenics Receives NASDAQ Delisting Notification - Business Wire 07.21.10 | 04:07 pm
- Encouraging Data Presented On Oncophage® Vaccine At International Conference On Brain Tumor Research And Therapy - Business Wire 05.20.10 | 07:05 am
- Antigenics To Webcast 2010 Annual Shareholders Meeting - Business Wire 04.29.10 | 07:04 am
- Antigenics Reports First Quarter 2010 Financial Results - Business Wire 04.29.10 | 07:04 am
- Antigenics To Report First Quarter Financial Results On April 29, 2010; Conference Call To Follow - Business Wire 04.22.10 | 07:04 am
- Antigenics To Report Fourth Quarter And Year-End 2009 Financial Results On February 18, 2010; Conference Call To Follow - Business Wire 02.11.10 | 07:02 am
Partner Headlines for AGEN
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 05.17.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 05.14.12 | 09:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Market Update - Benzinga 03.20.12 | 09:03 am
- Agenus Continues to Outperform - Seeking Alpha 03.16.12 | 06:03 pm
- 7 Biotech Stocks Being Snapped Up By Insiders - Seeking Alpha 03.16.12 | 05:03 pm
- Agenus Still Gaining On GSK Agreement Expansion - Seeking Alpha 03.15.12 | 08:03 am
- Insider Buys May Send The Wrong Signals - Seeking Alpha 08.22.11 | 09:08 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
- Antigenics changes name to Agenus - Reuters 01.06.11 | 01:01 pm





